|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Among these disorders, nystagmus and oculomotor dysfunction are increasingly recognized, although they have been rarely reported isolated or as the main manifestation of anti-GAD autoimmunity.
|
29501085 |
2018 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD (GADA) and islet antigen 2 (IA-2A) were assessed as markers of beta cell autoimmunity.
|
28364254 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A third endpoint was primary GAD autoimmunity defined as GAD autoantibody appearing as the first antibody without other concomitant autoantibodies (22 infants with GAD autoimmunity; 42 infants in control group).
|
28474159 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GAD65, but not GAD67, is a prevalent autoantigen, with autoantibodies to GAD65 being detected at high frequency in patients with autoimmune (type 1) diabetes and certain other autoimmune disorders.
|
24927554 |
2014 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
There was no difference in any of the TRPV1 variants by gender, age when type 1 diabetes was diagnosed, body mass index, glycemic control, blood pressure, positive autoantibodies (ICA, GAD, IAA), and other autoimmune diseases.
|
24340836 |
2013 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This report clearly illustrates the differences in terms of autoimmunity (prevalence and titer of GAD and IA2 antibodies) and HLA class II genotype between patients with LADA and those with juvenile type 1 diabetes.
|
17395515 |
2007 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Of the two homologous forms of glutamic acid decarboxylase, GAD65 and GAD67, only GAD65 is a common target of autoimmunity.
|
12865069 |
2003 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
On the OGTT, beta-cell function (as the ratio of insulin-to-glucose areas) was impaired ( p=0.02) only in association with anti-GAD positivity (3.2+/-3.1 U/mol, mean +/- SD) but not in anti- CD 38 positive patients (5.6+/-2.9) as compared with patients free of autoimmunity (4.5+/-4.6, p=NS).
|
12242463 |
2002 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Frequencies of autoimmunity characteristics (ICA or GAD-Ab positiveness and combination of autoimmune thyroid disease) were decreased in the R456H-positive patients compared to the R456H-negative patients.
|
10679252 |
2000 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These results show that DQB1*0302, the most important single IDDM susceptibility allele, is associated with a strong antibody response to IA-2 and insulin, while GAD-specific humoral autoimmunity is linked to the *02 allele, in common with a series of other autoimmune diseases as well as IDDM.
|
10209508 |
1999 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A possible connection between glutamate decarboxylase (GAD) autoimmunity and enterovirus infections in IDDM has been suggested to be based on a homology region between GAD and the non-structural protein 2C of coxsackievirus B4 (CVB4).
|
10588452 |
1999 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Different determinants in the HLA-DR locus contributed to the clinical onset of IDDM but not to GAD autoimmunity.
|
9404444 |
1997 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulin, glutamate decarboxylase (GAD) and the protein tyrosine phosphatase-like molecule IA-2 are major targets of humoral autoimmunity in insulin-dependent diabetes mellitus (IDDM).
|
8897011 |
1996 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
They suggest that GAD is an important target of autoimmunity associated with type 1 diabetes.
|
7614998 |
1995 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Although it has been confirmed that insulin dependent diabetes mellitus (IDDM) is a kind of autoimmune disease, islet cell autoantibodies (ICAs), insulin autoantibodies (IAA) and anti-GAD-glutamic acid decardaxylase antibodies have been found in the sera of patients with IDDM and immunotherapies have been used in some patients with IDDM, yet the manner in which the dysfunctional immunosystem acts on beta cells and causes damage to them remains to be clarified.
|
8143505 |
1993 |